Listed in Issue 265


CREUTZIG and COLLEAGUES, 1. Department of Pediatric Hematology/Oncology, Hannover Medical School, Children's Hospital, Hannover, Germany; 2. Department of Pediatrics, St. Anna Children's Hospital and Children's Cancer Research Institute, Medical University of Vienna, Vienna, Austria; 3. Division for Pediatric Hematology and Oncology, Johann Wolfgang Goethe-University, Frankfurt, Germany; 4. Department of Pediatric Hematology/Oncology, University Medicine of the Johannes Gutenberg-University Mainz, Mainz, Germany; 5. Division of Pediatric Hematology/Oncology, University Medical Center, Freiburg, Germany; 6. Department of Pediatric Oncology/Hematology, Saarland University, Homburg, Germany; 7. Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.

8. Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany; 9. Department of Pediatric Hematology and Oncology, Dr. von Hauner Children`s Hospital, Ludwig-Maximilians-University Munich, Munich, Germany; 10. Department of Pediatric Oncology/Hematology, Charité University Medical Center Berlin, Berlin, Germany; 11. Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany treated patients with standard-risk acute promyelocytic leukemia with arsenic trioxide and all-trans retinoid acid.


Recently, studies in adults with acute promyelocytic leukemia (APL) showed high cure rates in low-risk patients treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO).


toxicities were significantly reduced compared to the standard treatment with ATRA and chemotherapy.


Here we report about first experience with 11 pediatric patients with low-risk APL treated with ATRA and ATO. All patients stayed in molecular remission. All suffered from hyperleukocytosis. Two patients experienced reversible severe side effects. One suffered from osteonecroses at both femurs, seizures, as well as posterior reversible encephalopathy syndrome, the other patient had an abducens paresis [nerve palsy].



Creutzig U1, Dworzak MN2, Bochennek K3, Faber J4, Flotho C5, Graf N6, Kontny U7, Rossig C8, Schmid I9, von Stackelberg A10, Mueller JE11, von Neuhoff C11, Reinhardt D11, von Neuhoff N11. First experience of the AML-Berlin-Frankfurt-M√ľnster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. Pediatr Blood Cancer. 64(8). Aug 2017. doi: 10.1002/pbc.26461. Epub Jan 23 2017.

ICAN 2024 Skyscraper

Scientific and Medical Network 2

Cycle Around the World for Charity 2023

Climb Mount Kilimanjaro Charity 2023

top of the page